Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Durvalumab · 1 trial · 23 indications
Defined as the date of start of treatment to the date of death due to any cause. Will be analyzed using the Kaplan Meier method. Survival rate at 12 months and median OS will be estimated along with 95% confidence intervals from the Kaplan Meier distribution.
| Arm | Type | Description |
|---|---|---|
| Treatment (chemoimmunotherapy, FGFRi cycles) | EXPERIMENTAL | See Detailed Description |
| Name | Type | Description |
|---|---|---|
| Biospecimen Collection | PROCEDURE | Undergo blood sample collection |
| Cisplatin | DRUG | Given IV |
| Computed Tomography | PROCEDURE | Undergo CT scan |
| Durvalumab | BIOLOGICAL | Given IV |
| Gemcitabine | DRUG | Given IV |
| Magnetic Resonance Imaging | PROCEDURE | Undergo MRI |
| Pemigatinib | DRUG | Given PO |
| Survey Administration | OTHER | Ancillary studies |
Inclusion Criteria: * Adults 18 years of age or older with histologically or cytologically confirmed unresectable locally advanced or metastatic carcinoma of the biliary tract, including intrahepatic and extrahepatic cholangiocarcinoma, gallbladder, and ampulla of Vater, at the time of diagnosis * ...
Durvalumab is being studied for the treatment of locally advanced ampulla of Vater carcinoma, as well as other biliary tract cancers. It is part of an investigational combination regimen being evaluated in a Phase 2 clinical trial for patients with unresectable, locally advanced, or metastatic disease.
Durvalumab targets CD274, also known as PD-L1, and acts as an inhibitor of this protein. By inhibiting CD274, the drug is designed to interfere with the interaction between tumor cells and immune cells, which is a mechanism relevant to its use in oncology.
Durvalumab is being developed by Incyte Corporation, a biopharmaceutical company traded on the NASDAQ under the ticker symbol INCY. The company is conducting clinical research on this monoclonal antibody for the treatment of certain cancers, including locally advanced ampulla of Vater carcinoma.
Durvalumab is in Phase 2 clinical development for locally advanced ampulla of Vater carcinoma. The drug is investigational and has not been approved for this indication. It is being evaluated in an ongoing clinical trial that is currently recruiting participants.
Durvalumab is being studied in clinical trial NCT07780838, a Phase 2 study titled "Cyclical Gemcitabine, Cisplatin, and Durvalumab Alternating With Pemigatinib for the Treatment of Unresectable, Locally Advanced or Metastatic Biliary Tract Cancers With FGFR2 Alterations." This trial is recruiting participants in the United States and includes patients with locally advanced ampulla of Vater carcinoma.
Durvalumab is a monoclonal antibody that targets CD274. It is also known by the chemical identifier CHEMBL3301587. The drug is being investigated for its role in treating certain cancers, including locally advanced ampulla of Vater carcinoma, but it is not marketed under any other name in the context of this development program.